These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9531073)

  • 1. Influence of protein binding on the pharmacodynamics of ceftazidime or ceftriaxone against gram-positive and gram-negative bacteria in an in vitro infection model.
    Scaglione F; Demartini G; Arcidiacono MM; Dugnani S; Fraschini F
    J Chemother; 1998 Feb; 10(1):29-34. PubMed ID: 9531073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of amoxycillin/clavulanate (augmentin), ceftazidime and ceftriaxone against hospital strains of gram-negative and -positive bacteria.
    Abd-Elalim Eltahawy AT; Khalaf RM
    Chemioterapia; 1988 Apr; 7(2):75-8. PubMed ID: 3293818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal kinetics of an in vitro infection model of once-daily ceftriaxone plus amikacin against gram-positive and gram-negative bacteria.
    Scaglione F; Dugnani S; Demartini G; Arcidiacono MM; Cocuzza CE; Fraschini F
    Chemotherapy; 1995; 41(4):239-46. PubMed ID: 7555203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates.
    Washington JA; Jones RN; Allen SD; Gerlach EH; Koontz FP; Murray PR; Pfaller MA; Erwin ME
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1508-11. PubMed ID: 1929319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.
    Hanberger H
    Scand J Infect Dis Suppl; 1992; 81():1-52. PubMed ID: 1322561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of ceftriaxone- and ceftazidime-resistant gram-negative bacteria in long-term-care facilities.
    Mody L; Bradley SF; Strausbaugh LJ; Muder RR
    Infect Control Hosp Epidemiol; 2001 Apr; 22(4):193-4. PubMed ID: 11379705
    [No Abstract]   [Full Text] [Related]  

  • 9. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
    Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
    J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In-vitro activity of ceftriaxone on Gram-negative bacilli with various resistance phenotypes to cephalosporins. Comparison with cefotaxime, cefmenoxime, moxalactam, ceftazidime].
    Rouhan D; Le Noc P; Le Noc D
    Pathol Biol (Paris); 1986 May; 34(5):404-9. PubMed ID: 3534713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of ceftazidime compared with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():57-62. PubMed ID: 19810169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Activity of 3 cephalosporins on gram-negative bacterial flora isolated in a hospital environment].
    Garino M; Pizzo L; Lollini P; Angela GC
    G Ital Chemioter; 1985; 32(3):525-30. PubMed ID: 3915490
    [No Abstract]   [Full Text] [Related]  

  • 13. Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro.
    Soren O; Brinch KS; Patel D; Liu Y; Liu A; Coates A; Hu Y
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6233-40. PubMed ID: 26248380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of ceftazidime and four other cephalosporins against gram-negative bacteria and their sensitivity to beta-lactamases.
    Galante D; Esposito S; Barba D; Pennucci C; Limauro D; Scioli C
    Chemioterapia; 1984 Aug; 3(4):250-4. PubMed ID: 6398123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum beta-lactamase-mediated resistance among bacterial isolates recovered from ocular infections.
    Jayahar Bharathi M; Ramakrishnan R; Ramesh S; Murugan N
    Ophthalmic Res; 2012; 47(1):52-6. PubMed ID: 21720185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of clinical isolates of gram-positive and gram-negative organisms to cefatrizine.
    Carlone NA; Cuffini AM; Forno Pizzoglio M; Cavallo G
    Drugs Exp Clin Res; 1985; 11(7):447-51. PubMed ID: 3836867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carumonam's in-vitro activity against gram-negative bacteria and its stability to their beta-lactamases.
    Raimondi A; Mattina R; Cocuzza CE
    Chemioterapia; 1988 Feb; 7(1):3-9. PubMed ID: 3288365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA; Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.